Clinical TrialID 8254
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
NCT05809336
Advanced Solid Tumor
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8254
- Evidence Id
- 8254
- Core Evidence Id
- 8254
- Source Clinical Trial Id
- 8252
- Herb2 Clinical Trial Id
- HBCT008252
- Nct Id
- NCT05809336
- Title
- Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 2|Phase 3
- Study Result
- No
- Study Condition
- Advanced Solid Tumor
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: Inosine 0.2g orally 3 times/day|DRUG: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 172
- Outcome Measure
- overall survival (OS), Time from randomization grouping to death from any cause, 36 months|progression-free survival (PFS), Time from randomization grouping to the first recorded disease progression or death from any cause, 36 months
- Sponsor Collaborator
- Beijing Friendship Hospital
- Funded By
- OTHER
- Location
- Qin li, Beijing, Beijing, 100029, China
- Other Id
- Beijing inosine
- Start Date
- 2019-05-01
- Primary Completion Date
- 2022-10-31
- Completion Date
- 2022-10-31
- First Posted
- 2023-04-12
- Results First Posted
- Last Update Posted
- 2023-04-12
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05809336
- Title Cn
- Title En
- Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
- Bilingual Status
- semi_complete